Michael Thomas Heffernan - 03 Oct 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Oct 2022, 20:26:27 UTC
Prior SEC filing
30 Sep 2022
Next SEC filing
14 Dec 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ George Clark, Attorney-in-Fact

Key filing fact

Michael Thomas Heffernan filed Form 4 for Biohaven Pharmaceutical Holding Co Ltd. on 03 Oct 2022.

Key facts

  • This page summarizes Michael Thomas Heffernan's Form 4 filing for Biohaven Pharmaceutical Holding Co Ltd..
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 03 Oct 2022, 20:26.

Change

  • Previous filing in this sequence was filed on 30 Sep 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BHVN transaction Derivative

Restricted Share Unit Award

Disposed to Issuer

Transaction value
Shares
-3,320
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
3,320
Exercise price
Footnotes
F1, F2
BHVN transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-8,239
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
8,239
Exercise price
$95.33
Footnotes
F3
BHVN transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-11,996
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
11,996
Exercise price
$70.17
Footnotes
F3
BHVN transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-26,200
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
26,200
Exercise price
$47.30
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

Footnote F2

In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

Footnote F3

In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .